

TRANSPARENCY IN ANIMAL USE

RESOLVED, that the Board issue an annual report to shareholders detailing measures taken to ensure that Amgen's animal experimentation oversight committee functions properly with regard to the use of animals in painful and lethal experiments, procedures to ensure appropriate animal care in-house and at contract laboratories, and specifics on how Amgen uses animals and plans to promote alternatives to animal use.

Supporting Statement:

Our Company posts a number of public policies on its website.¹ Our environmental policy, for example, provides specific data on compliance issues, energy use,² and conservation targets. Goals for fuel efficiency, recycling, and waste reduction are clearly articulated.³ Environmental notices of violations are reported.⁴

In contrast, our Company's animal testing policy is composed solely of generic statements and provides no specific information.⁵ Unlike other international companies,⁶ it does not provide details such as animal use numbers or specific efforts to incorporate replacement methods.

Publicly available government documents show that our Company's animal experimentation oversight committee—required by law to review experiments and ensure compliance with applicable laws—is not functioning properly. This committee is the animals' last line of defense, yet it is not scrutinizing our Company's animal use as required.

Of the thousands of animals used in the past four years by our Company, a staggering 64% were used in painful experiments. In 2011, our Company's oversight committee was cited for failing to properly oversee painful and invasive experiments that involved exposing animals' blood vessels and inserting tubes into them. It was also cited for failing to review significant changes to experimental protocols involving dogs.

Our Company states that it "exercises diligent animal welfare oversight for sponsored work at contract research organizations." Yet in one contract laboratory used by our Company, Covance, Inc., an undercover investigator videotaped workers striking primates and throwing them against cages. Primates circled frantically in their cages, pulled out their hair, and chewed at their own flesh.⁷

In another instance, a primate became trapped in his cage bars, unable to reach food or water for days, while others suffered frostbite from inadequate weather protection. The

¹ http://www.amgen.com/about/corporate_compliance.html

² <http://www.amgen.com/about/environment/performance.html>

³ <http://www.amgen.com/about/environment/targets.html>

⁴ <http://www.amgen.com/about/environment/compliance.html>

⁵ http://www.amgen.com/science/ethical_research.html

⁶ http://www.novonordisk.com/science/bioethics/animal_ethics.asp

⁷ <http://www.covancecruelty.com>

government has cited and fined Covance for improper care and failure to provide pain relief to suffering animals.

Given that 92% of drugs deemed safe and effective when tested on animals fail in human clinical trials and that, of the remaining 8%, half are later relabeled or withdrawn due to unanticipated, severe adverse effects, there is also a clear scientific imperative for improving how our Company's products are tested.⁸

Our Company must incorporate recommendations from the National Academy of Sciences to use recent scientific advances to “transform toxicity testing from a system based on whole-animal testing to one founded primarily on *in vitro* [non-animal] methods.”⁹ These approaches will improve efficiency and predictivity to humans, and reduce animal use and suffering as well as cost.

We urge shareholders to vote **FOR** this proposal.

⁸ FDA Commissioner: <http://www.fda.gov/oc/speeches/2006/fdateleconference0112.html>

⁹ *Toxicity Testing in the 21st Century: A Vision and a Strategy* (NRC 2007)